# Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

> **NCT04739826** · — · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 491 (estimated)

## Conditions studied

- CML, Chronic Phase; TKI

## Interventions

- **DRUG:** Flumatinib Mesylate
- **DRUG:** Nilotinib Pill

## Key facts

- **NCT ID:** NCT04739826
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-25
- **Primary completion:** 2025-01
- **Final completion:** 2025-12
- **Target enrollment:** 491 (ESTIMATED)
- **Last updated:** 2023-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04739826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04739826, "Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04739826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*